Shared on 19 Nov 25
Fair value Increased 6.25%SUPRIYA: Future Performance To Reflect Improved Margins And WHO-GMP Certification
Analysts have raised their price target for Supriya Lifescience from ₹800 to ₹850, citing stronger revenue growth projections and improved profit margins. What's in the News The board meeting is scheduled for November 12, 2025 to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025.
Shared on 23 Aug 25
Fair value Decreased 5.10%Despite a substantial increase in consensus revenue growth forecasts and a notable reduction in future P/E, analysts have revised Supriya Lifescience’s fair value down from ₹843 to ₹800. What's in the News Board meeting scheduled to approve unaudited financial results for the quarter ended June 30, 2025.
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 4.24%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 13 Mar 25
Fair value Decreased 12%AnalystConsensusTarget made no meaningful changes to valuation assumptions.